yahoo_financeOriginal article
Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE
positiveDupixentPositive
AI Analysis
Summary
Regeneron announced positive Phase 4 trial results for Dupixent showing improved esophageal function in patients with eosinophilic esophagitis (EoE). The data supports the continued development of Dupixent in this indication.
Clinical Trial Data
Phase
Phase 4
Primary Endpoint
Met
Outcome Details
Improved esophageal function demonstrated
Importance:6/10
Sentiment:
0.70
DupixentEoEPhase 4esophageal functionpositive data
Related Companies
Read the original article
Published by yahoo_finance on May 5, 2026 2:14 PM